Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | GALR2 | O43603 | 1/20 | 0.48 |
| ▸ | GALR1 | P47211 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293389 | 0.91 | SMN1; SMN2 (0.53) | GBA1CTSLCTSSCTSKGALR2 | |
| SCHEMBL3287378 | 0.87 | CTSS (0.56) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL3287006 | 0.86 | CTSL (0.61) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL13325957 | 0.85 | CTSS (0.54) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL3289389 | 0.85 | CTSL (0.68) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL3291713 | 0.83 | GALR2 (0.67) | GBA1CTSLCTSSCTSKGALR2 | |
| SCHEMBL13359695 | 0.83 | APP (0.57) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL3290340 | 0.82 | CTSL (0.57) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL3287809 | 0.82 | CTSL (0.54) | CTSLCTSSCTSKGALR2GALR1 | |
| SCHEMBL13326070 | 0.81 | PDE4A (0.53) | CTSLCTSSCTSKGALR2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718655-B2 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718655-B2 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718655-B2 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-20040122009-A1 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122009-A1 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | TUBA1C, TUBB1, TUBB | GBA1 1245/4885CTSL 1884/4885CTSS 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.